Some studies are important because of how they change things. Others are important because of the questions they ask. The 2016 study by Roland Griffiths and his team at Johns Hopkins is one of those studies. They wanted to know if a single high dose of psilocybin could help people with cancer feel less depressed and anxious. The answer they found was very interesting.
This article will take the study apart. Put it back together. We will look at what the researchers did what they found and what it means. The Griffiths 2016 Trial is one of the important studies on psilocybin. It is an example of how to read a study like this.
Why the study was done
To understand why a serious academic center would study a Schedule I substance like psilocybin we need to look at the problem they were trying to solve. A cancer diagnosis is not just bad for the body. It can also be very hard on the mind. People with cancer often feel depressed, anxious and scared. These feelings can be very hard to deal with. The usual treatments for depression and anxiety do not always work well for people with cancer.
The researchers at Johns Hopkins had already done some work on psilocybin. They had found that it could be given safely to people in a controlled environment. They had also found that it could cause meaningful experiences. The 2016 trial was a way to build on this work. The team was led by Roland Griffiths. They were careful and thorough in their approach.
What the researchers did
The study had 51 participants, all of whom had cancer and were feeling depressed or anxious. The participants were given either a dose of psilocybin or a very low dose. The order of the doses was randomized so some people got the dose first and some got the low dose first. The participants did not know which dose they were getting.
The psilocybin was not given on its own. It was part of a process that included preparation, support and follow-up. The participants were prepared for the experience beforehand and had support during and after. The experience was designed to be comfortable and meaningful.
The researchers used established measures to track the participants depression, anxiety and quality of life. They also looked at how the participants felt about death and their sense of meaning and purpose. The researchers followed up with the participants six months after the study to see how they were doing.
What the researchers found
The results of the study were very interesting. The participants who got the dose of psilocybin had significant reductions in depression and anxiety. The effects were still there six months later. The participants also reported improvements in their quality of life sense of meaning and attitudes toward death. Many of the participants said that the psilocybin experience was one of the meaningful experiences of their lives.
The study found that the depth of the psilocybin experience was linked to the degree of improvement. This suggests that the therapeutic effect of psilocybin may be related to the experience it causes. The Griffiths 2016 Trial was a study that helped to establish psilocybin as a potential treatment for depression and anxiety in people, with cancer.
The last connection between psilocybin and depression is really interesting and also of tricky. It seems like the experience people have when they take psilocybin is what helps them feel better not the psilocybin itself. If people have a meaningful experience they are more likely to feel less depressed. This is a big deal and it is part of what makes this research so interesting to people who study consciousness and mood.
We have to be careful when we look at this connection. Just because there is a connection between the depth of the experience and the size of the benefit it does not mean that the experience is what caused the benefit. Some people might be more likely to have an experience and also be more likely to feel better. We do not know for sure what's causing what.
Pull quote: One dose of psilocybin and six months later most people were still less depressed and less afraid of dying. This is what made people in the field take notice.
The research on safety was good. There were no problems caused by the psilocybin. Some people felt uncomfortable or anxious during the sessions. This was managed and did not cause any lasting harm. The increase in blood pressure and heart rate was. Did not cause any problems. The important thing is that the psilocybin was safe when used in a controlled setting.
Another study was published on the day
One thing that people often miss is that this study was not the only one. Another study was published on the day led by Stephen Ross and colleagues at New York University. This study also looked at psilocybin for depression and anxiety in cancer patients. The fact that two separate teams got results is important. It means that the results are more reliable and not just a one-time thing.
This is important because when two separate groups get the result it is harder to say that it was just a coincidence. It is like a test of whether the results can be repeated and that is what makes research more believable. Neither study was large. Together they carried more weight.
What the study did well
The study was well-designed. Made some good choices. The way the study was set up with each person being their control was smart. Using a dose of psilocybin as a comparison was a good way to try to solve the problem of people knowing what they were taking. The follow-up after six months was also a strength because it showed that the benefits lasted. The decision to treat psilocybin as part of a process rather than just a drug was also a good one.
The measures used to assess the results were established and validated which makes it easier to compare the results to research. The safety monitoring was careful. The authors were honest about the studys limits. This is important because good research should know its weaknesses and say so.
What the study struggled with
Now the part. No single study can answer all the questions. This one is no exception. The biggest problem is that people could often tell when they were taking the dose of psilocybin because it has unmistakable effects. This means that peoples expectations could influence the results and that is a problem. The study could not separate the effects of the drug from the effects of peoples expectations.
The study also had an selected group of participants. Fifty-one people were in the study and they were not a random group of cancer patients. They were people who were willing to try an unusual treatment and that might mean that they were more likely to benefit. We do not know if the results would be the same for a more diverse group of people.
Then there is the problem of the "bundle”. The combination of psilocybin, therapy and support. The study tested the package, not just the psilocybin. This means that we do not know how much of the benefit came from the psilocybin and how much from the parts of the treatment.
It is hard to separate the effects of the psilocybin from the effects of the therapy and support because they are all connected. Imagine giving someone a day of attention and support with permission to explore their feelings and thoughts. That would likely have a benefit without the psilocybin. This is why it is hard to say exactly what caused the benefits in the study.
What the study. What it does not mean
If we look at the study carefully we can see what it really means. It means that psilocybin-assisted therapy might be a treatment for depression and anxiety in cancer patients. It means that we should take this idea seriously and do research. It also means that the results of this study, combined with the results of the study are a good reason to invest in more research in this area.
It does not mean that psilocybin is a proven treatment. It does not mean that we can just start using it without control and support.. It does not mean that we have found a cure. The study was promising,. It was also limited. We need to be careful and not get ahead of ourselves.
Why this study still matters
The study is still important with its limitations. It showed that psilocybin-assisted therapy might be a treatment for depression and anxiety in cancer patients. It also showed that this treatment can be safe when used in a controlled setting. The study might not have answered all our questions. It is a starting point, for more research.. That is what matters.
The Griffiths 2016 trial is still a part of the story about psilocybin research for a few good reasons. It was one of the studies that helped make psilocybin research respectable again after years. The Griffiths 2016 trial showed that a serious academic group could do an ethical study of a Schedule I psychedelic like psilocybin and publish results that people could not easily ignore. The Griffiths 2016 trial also focused on people who were very sick and near the end of their lives which's a group that regular psychiatry has not been able to help very much.
The Griffiths 2016 trial also showed a way to do this kind of research with a structured program and honest talk about what the study could and could not do. Many other studies have built on the Griffiths 2016 trial. It is also a moving study and it is okay to say that without stopping being skeptical. The idea of people who're near death finding some peace after just one guided session with psilocybin is really powerful.
We need to balance the side of this study with the need to be careful and skeptical. The Griffiths 2016 trial is the beginning, not the end. There are studies happening now that will either confirm or change what the Griffiths 2016 trial found. To understand these studies we need to pay attention to how they are designed and be respectful of their limits.